Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021. (8th February 2023)

• Record Type: Journal Article
• Authors: Simonneau, Gérald; Fadel, Elie; Vonk Noordegraaf, Anton; Toshner, Mark; Lang, Irene M.; Klok, Frederikus A.; McInnis, Micheal C.; Screaton, Nicholas; Madani, Michael M.; Martinez, Guillermo; Salaunkey, Kiran; Jenkins, David P.; Matsubara, Hiromi; Brénot, Philippe; Hoeper, Marius M.; Ghofrani, Hossein A.; Jaïs, Xavier; Wiedenroth, Christoph B.; Guth, Stefan; Kim, Nick H.; Pepke-Zaba, Joanna; Delcroix, Marion; Mayer, Eckhard
• Is Part Of: European respiratory review. Volume 32:Number 167(2023)
• Publication Date: 2023-02-08
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Electronic journals; Periodical; Periodicals; Periodicals; 616.2
• DOI: 10.1183/16000617.0132-2022
• Languages: English
• ISSNs: 0905-9180

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism. It is caused by persistent obstruction of pulmonary arteries by chronic organised fibrotic clots, despite adequate anticoagulation. The pulmonary hypertension is also caused by concomitant microvasculopathy which may progress without timely treatment. Timely and accurate diagnosis requires the combination of imaging and haemodynamic assessment. Optimal therapy should be individualised to each case and determined by an experienced multidisciplinary CTEPH team with the ability to offer all current treatment modalities. This report summarises current knowledge and presents key messages from the International CTEPH Conference, Bad Nauheim, Germany, 2021. Sessions were dedicated to 1) disease definition; 2) pathophysiology, including the impact of the hypertrophied bronchial circulation, right ventricle (dys)function, genetics and inflammation; 3) diagnosis, early after acute pulmonary embolism, using computed tomography and perfusion techniques, and supporting the selection of appropriate therapies; 4) surgical treatment, pulmonary endarterectomy for proximal and distal disease, and peri-operative management; 5) percutaneous approach or balloon pulmonary angioplasty, techniques and complications; and 6) medical treatment, including anticoagulation and pulmonary hypertension drugs, and in combination with interventional treatments. Chronic thromboembolic pulmonary disease without pulmonary hypertension is also discussed in terms of its diagnostic and therapeutic aspects. This report summarises current knowledge on chronic thromboembolic pulmonary hypertension (CTEPH) and presents key messages from the International CTEPH Conference, Bad Nauheim, Germany, 2021. https://bit.ly/3VJmc2l